Metastasis in renal cell carcinoma: Biology and implications for therapy
| dc.contributor.author | Gong, Jun | |
| dc.contributor.author | Maia, Manuel Caitano | |
| dc.contributor.author | Dizman, Nazli | |
| dc.contributor.author | Govindarajan, Ameish | |
| dc.contributor.author | Pal, Sumanta K. | |
| dc.date.accessioned | 2025-05-10T19:48:28Z | |
| dc.date.issued | 2016 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description.abstract | Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. | |
| dc.description.sponsorship | Pfizer; Novartis; Aveo; Genentech; Exelixis; BMS; Astellas; GSK | |
| dc.description.sponsorship | Dr. Pal receives honoraria from Novartis, Medivation and Astellas Pharma, and receives consulting fees from Pfizer, Novartis, Aveo, Genentech, Exelixis, BMS, Astellas and GSK. | |
| dc.identifier.doi | 10.1016/j.ajur.2016.08.006 | |
| dc.identifier.endpage | 292 | |
| dc.identifier.issn | 2214-3882 | |
| dc.identifier.issn | 2214-3890 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pmid | 29264197 | |
| dc.identifier.scopus | 2-s2.0-85027839647 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 286 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ajur.2016.08.006 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/11702 | |
| dc.identifier.volume | 3 | |
| dc.identifier.wos | WOS:000390819500015 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Singapore Pte Ltd | |
| dc.relation.ispartof | Asian Journal of Urology | |
| dc.relation.publicationcategory | Diğer | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.subject | Renal cell carcinoma | |
| dc.subject | Metastasis | |
| dc.subject | Vascular endothelial growth factor | |
| dc.subject | Mammalian target of rapamycin | |
| dc.subject | Hypoxia inducible factor | |
| dc.title | Metastasis in renal cell carcinoma: Biology and implications for therapy | |
| dc.type | Review |
Dosyalar
Orijinal paket
1 - 1 / 1










